Le Lézard
Classified in: Environment, Health
Subjects: ENI, ENP, ANW, CFG

Health Canada launches consultation on use of imidacloprid pesticide


Some uses of this neonicotinoid are proposed for phase out to protect bees and other pollinators

OTTAWA, May 31, 2018 /CNW/ - Canadians care about how the use of pesticides impacts the environment. The Government of Canada relies on scientific evidence to evaluate pesticides so that they are used safely and do not threaten human health or the environment. With that in mind, the Government of Canada is consulting Canadians on its latest proposal to protect bees and other pollinators from exposure to imidacloprid, a neonicotinoid pesticide.

Health Canada's scientific assessment of imidacloprid looked at the effects of this pesticide on pollinators such as honey bees, bumble bees and solitary bees. The assessment found that there are some uses of imidacloprid that may pose a risk to bees. The Department is therefore proposing significant restrictions on the use of imidacloprid products to protect bees and other pollinators. These proposed restrictions include the cancellation of some uses, restrictions on the timing of use, and new product labels.

Consultations on this proposed decision will be open to the public for 90 days. Comments received during this consultation will be considered along with input from previous consultations, including separate restrictions that were proposed in 2016 to protect aquatic insects. We expect to publish a final decision on the overall use of imidacloprid in Canada in December 2018.

Health Canada's primary objective in regulating pesticides is to protect the health of Canadians and the environment. All pesticides must undergo a rigorous science-based review before being approved for sale in Canada.

Quick Facts

Related Products
Backgrounder: Proposed Re-evaluation Decision: Imidacloprid ? Pollinator (Bee) Assessment

Associated Links
PRVD2018-12: Proposed Re-evaluation Decision on Imidacloprid (Pollinator Assessment) 
PRVD2016-20: Proposed Re-evaluation Decision on Imidacloprid 
December 2017 Update on Neonicotinoid Pesticides
PRVD2017-23: Proposed Re-evaluation Decision on Clothianidin and Its Associated End-use Products: Pollinator Re-evaluation 
PRVD2017-24: Proposed Re-evaluation Decision on Thiamethoxam and Its Associated End-use Products: Pollinator Re-evaluation 
Update on Bee Incident Reports 2012-2016

 

SOURCE Health Canada


These press releases may also interest you

at 09:20
China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered...

at 09:08
MyFitnessPal, the #1 global nutrition and food tracking app, today announced that it has appointed Tim Holley as Chief Product Officer. In this role, Tim will apply his extensive experience driving sustained growth through reliable delivery of...

at 09:05
MDI Health, an AI-powered solution that optimizes personalized medication management at scale, announced that it has been selected as winner of the "Best New Technology Solution for Medication Management" award in the 8th annual MedTech Breakthrough...

at 09:02
Lumenis Be Ltd., a leading energy-based medical device company for aesthetic and eye care applications, announced today that triLift is the winner of the highly competitive "Best New Dermatology Technology Solution" award in the 8th annual MedTech...

at 09:00
Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024...

at 09:00
Medtech Canada, the national association representing Canada's medical technology companies, is very pleased to welcome James Brodie of Johnson & Johnson MedTech as Chair of the Medtech Canada Board of Directors. He is joined by five new board...



News published on and distributed by: